Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ElsaLys Biotech SAS

www.elsalysbiotech.com/

Latest From NeoProbe-Israel

Manufacturing issues plague Navidea cancer tracing agent; FDA rejects

Shares of Navidea Biopharmaceuticals plummeted 35% on 11 September following the firm's revelation after the markets closed the day before that the US FDA had rejected the company's new drug application (NDA) for its radioactive diagnostic tracing agent Lymphoseek (tilmanocept) for use in intraoperative lymphatic mapping (ILM), a surgical oncology procedure used primarily in patients with breast cancer and melanoma to determine if disease has spread to the lymph nodes.

Cancer

Navidea tumbles on extended US FDA review for radioactive tracing agent

Shares of Navidea Biopharmaceuticals, formerly known as Neoprobe, tumbled as low as 11.85%, or 39 cents, on 3 April, after the Dublin, Ohio-based firm said the US FDA extended by three months the Prescription Drug User Fee Act (PDUFA) action date for the new drug application (NDA) for the company's radioactive diagnostic tracing agent Lymphoseek (tilmanocept) for use in intraoperative lymphatic mapping (ILM), a surgical oncology procedure used primarily in patients with breast cancer and melanoma to determine if disease has spread to the lymph nodes.

Cancer

Yaupon, Neoprobe, Intendis adopt new names

Three biopharmas started 2012 by christening their firms with new names.

Cancer

Neoprobe leaps on US FDA acceptance of cancer diagnostic agent NDA

Shares of Neoprobe jumped as high as 21%, or 55 cents, on 20 October, after the firm revealed that the US FDA accepted the company's new drug application (NDA) for its radioactive diagnostic tracing agent Lymphoseek (tilmanocept) for use in intraoperative lymphatic mapping (ILM), a surgical oncology procedure used primarily in patients with breast cancer and melanoma to determine if disease has spread to the lymph nodes.

Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • ElsaLys Biotech SAS
  • Senior Management
  • Christine Guillen, CEO
    Jacques Mizrahi, PhD, VP, R&D
    Liliane Bronstein, VP, Fin.
    Catherine Mathis, COO
  • Contact Info
  • ElsaLys Biotech SAS
    Phone: 4 37 28 73 00
    321 avenue Jean Jaurès
    Lyon, 69007
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register